Idorsia (XSWX:IDIA) Quality Rank


XSWX:IDIA Idorsia Ltd XSWX:IDIA
48 GF Score
Price CHF6.40
GF Value CHF2.87
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Idorsia Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Idorsia Quality Rank Related Terms

XSWX:IDIA
48GF Score
Idorsia Ltd XSWX:IDIA
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Idorsia (XSWX:IDIA) Overvalued in 2026?

Based on GuruFocus' analysis, Idorsia stock appears to be overvalued. The current stock price of CHF6.40 is trading 122.8% above its estimated GF Value™ of CHF2.87. GuruFocus considers Idorsia to be Significantly Overvalued.

Key valuation signals for XSWX:IDIA:

  • Quality Rank:
  • GF Value™: CHF2.87 vs. price of CHF6.40 (122.8% above fair value)
  • GF Score™: 48/100 with 3 warning signs

No single metric tells the full story. See the XSWX:IDIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Idorsia Business Description

Address Hegenheimermattweg 91, Allschwil, CHE, 4123
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. The company is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide new therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. The company's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.
48GF Score

Get the complete analysis for XSWX:IDIA

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF6.40
Price
CHF2.87
GF Value